Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

LENZ Therapeutics (LENZ) Equity Average (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Equity Average for 4 consecutive years, with $239.1 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 14.05% to $239.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $239.1 million through Dec 2025, up 14.05% year-over-year, with the annual reading at $244.2 million for FY2025, N/A changed from the prior year.
  • Equity Average for Q4 2025 was $239.1 million at LENZ Therapeutics, up from $200.1 million in the prior quarter.
  • The five-year high for Equity Average was $349.9 million in Q2 2022, with the low at -$60.4 million in Q3 2023.
  • Average Equity Average over 4 years is $157.1 million, with a median of $198.6 million recorded in 2025.
  • The sharpest move saw Equity Average crashed 118.44% in 2023, then soared 544.98% in 2024.
  • Over 4 years, Equity Average stood at $146.1 million in 2022, then crashed by 141.32% to -$60.4 million in 2023, then surged by 447.22% to $209.7 million in 2024, then grew by 14.05% to $239.1 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $239.1 million, $200.1 million, and $199.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.